214 studies on Liraglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This Phase 3 trial is crucial for optimizing Type 2 Diabetes management by evaluating a potentially simpler, yet effective, treatment option. If IDegLira demonstrates comparable efficacy and a favorable safety profile…
This study provides strong evidence supporting the enhanced efficacy of combining a basal insulin (insulin degludec) with a GLP-1 receptor agonist (liraglutide, a class of drugs that mimic a natural hormone to lower b…
The key implication of this research is the potential for IDegLira to offer a significantly safer and more effective therapeutic option for Type 2 Diabetes patients transitioning from hospital to home. By reducing the…
This pilot study provides compelling preliminary evidence that liraglutide could offer a novel therapeutic approach for sleep apnea in non-diabetic individuals, potentially independent of its weight-loss effects. The …
This comprehensive evaluation provides critical evidence supporting the superior efficacy of certain long-acting GLP-1 RAs in managing Type 2 Diabetes, particularly concerning glycemic control and weight reduction. Th…
This research highlights critical areas for intervention to optimize patient education and improve outcomes for individuals using Saxenda®. Addressing the identified barriers, such as time constraints and lack of stan…
This comprehensive review underscores the immense potential of novel drug targets, innovative drug classes, and cutting-edge technologies to revolutionize the treatment landscape for metabolic diseases. The insights g…
These findings establish hypothalamic Cav3.1 as a crucial neuronal leucine sensor, providing a novel and fundamental understanding of how dietary protein influences satiety and body weight. This discovery suggests tha…
This study highlights Dapagliflozin's potential as a valuable adjunctive therapy for Type 1 Diabetes patients struggling with optimal glycemic control despite existing Insulin and Liraglutide regimens. The observed be…
This pilot study represents a novel approach to Type 2 Diabetes Mellitus management, focusing on an intensive, short-term intervention to potentially reverse or significantly improve disease progression. If successful…
These hypothetical findings suggest that GLP-1 receptor agonists like Liraglutide or GIK infusions could offer safer and more effective perioperative glycemic control for patients with Type II Diabetes Mellitus underg…
Understanding the real-world effectiveness of combination therapies like Xultophy® is crucial for optimizing Type 2 Diabetes management. This study provides valuable data on how a fixed-ratio combination of insulin de…
This study provides valuable real-world evidence regarding the effectiveness and utilization of liraglutide for weight management outside of controlled clinical trial settings. The findings can help inform healthcare …
Developing long-acting GLP-1 receptor agonists is paramount for improving patient adherence and convenience in the long-term management of Type 2 Diabetes. If LAPS-Exendin (HM11260C) demonstrates favorable safety and …
This study is significant because it investigates strategies to improve the long-term management of Type 2 Diabetes, moving beyond conventional insulin regimens. The expected findings suggest that combining insulin wi…
This research solidifies Liraglutide's role as a cornerstone therapy for managing Type 2 Diabetes and Obesity, offering not only robust glycemic control and significant weight reduction but also crucial cardiovascular…
This comprehensive critique offers crucial insights for clinicians and patients, suggesting that the current evidence does not strongly support a direct causal link between GLP-1 RAs and NAION, which may help alleviat…
This study highlights a critical safety consideration for patients undergoing free flap breast reconstruction who are also using GLP-1 RAs. The observed increase in serious wound complications, particularly flap necro…
This study highlights a critical safety signal, suggesting that GLP-1 receptor agonists may be associated with an increased risk of depressed mood and suicidal ideation in real-world settings. This finding underscores…
The findings from this study are crucial because they will inform the safe and effective use of AD109 in a growing population of OSA patients who are also managing their weight or diabetes with GLP-1 medications. If A…
This study provides compelling evidence that PPARγ and GLP1 receptor agonists can directly improve brain metabolism and neuronal mitochondrial function, offering a novel therapeutic avenue for cognitive health. The us…
This comprehensive analysis provides crucial evidence for clinicians and patients in selecting the most effective GLP-1 receptor mono-agonist formulation for cardiometabolic improvement. The findings highlight the sup…
This systematic review underscores the transformative potential of GLP-1 receptor agonists in the management of obesity and its associated health complications. The consistent and significant weight loss observed, cou…
Understanding the sex-based heterogeneity in drug response is crucial for optimizing personalized medicine approaches in CKMH. If significant differences are found, it could lead to sex-specific prescribing guidelines…
This study is crucial because it seeks to uncover a novel mechanism by which semaglutide promotes weight loss, specifically through its impact on brown adipose tissue (BAT). Understanding this pathway could lead to mo…
This study provides valuable real-world insights into the comparative safety profiles of tirzepatide, semaglutide, and liraglutide, which can complement findings from controlled clinical trials. The observed differenc…
This network meta-analysis provides crucial evidence that could significantly impact clinical guidelines for managing Type 2 Diabetes patients with high cardiovascular risk. The identification of specific GLP-1 recept…
This research provides robust real-world evidence confirming the effectiveness of GLP-1 therapies in a diverse Middle Eastern population, mirroring results from controlled clinical trials. The observed significant red…
This research provides a more robust and accurate framework for predicting the efficacy and optimizing the dosing of GLP-1 receptor agonists like liraglutide. By precisely accounting for target-mediated drug dispositi…
The findings from this trial are profoundly significant, as oral semaglutide offers a highly effective, non-injectable treatment option for Type 2 Diabetes Mellitus. This oral formulation has the potential to revoluti…
This real-world comparative study provides crucial insights into the relative effectiveness of leading weight loss medications outside of controlled clinical trials. The findings strongly support Tirzepatide's superio…
This comprehensive network meta-analysis provides robust evidence confirming the superior efficacy of GLP-1 receptor agonists in achieving clinically significant weight loss in nondiabetic adults. The findings highlig…
This comprehensive review underscores the significant potential of GLP-1 RAs as novel therapeutic agents for a range of psychiatric disorders, extending their utility beyond metabolic health. Their established safety …
This retraction is a critical reminder of the importance of scientific integrity and rigorous peer review in maintaining the reliability of medical literature. It underscores that any conclusions or recommendations ba…
This review provides a strong theoretical and preliminary clinical basis for exploring GLP-1 RAs as novel adjuncts to cancer immunotherapy. The observed immunomodulatory effects and potential for enhanced efficacy, co…
If the anticipated findings are confirmed, this study could provide crucial evidence for the broad metabolic benefits of GLP-1RAs beyond just glycemic control and weight loss. A detailed understanding of how these dru…
The study aimed to demonstrate that tirzepatide significantly impacts food intake and modulates brain activity in areas associated with appetite and reward. While specific quantitative results are not detailed in this…
Preventing muscle loss during significant weight reduction is critical for long-term health outcomes, as preserved muscle mass contributes to better metabolic function, strength, and overall quality of life. If succes…
This exploratory analysis suggests liraglutide could offer a multi-faceted therapeutic approach for individuals grappling with the complex and often debilitating combination of obesity, OSA, and COPD. By effectively p…
This comprehensive review highlighted the diverse and innovative approaches being explored to combat obesity in the early 2000s. The identification of multiple drug classes, from central nervous system modulators to p…
This comprehensive meta-analysis strongly reinforces Liraglutide's established role as an effective and safe treatment for T2DM, offering significant benefits beyond glycemic control, including clinically meaningful w…
This large-scale, real-world data provides crucial insights into the safety profile of GLP-1 receptor agonists when exposure occurs around conception. The reassurance regarding major congenital malformations is partic…
This study provides compelling evidence that GLP-1 RAs offer significant benefits beyond metabolic control, extending to crucial aspects of mental health and cognitive function. These findings suggest a potential for …
This research provides compelling evidence that GLP-1RAs possess direct antiarrhythmic properties, significantly extending their known cardiovascular benefits beyond glycemic control and weight loss. The observed subs…
This research underscores the chronic nature of obesity and highlights that GLP-1 receptor agonists function as effective long-term management tools rather than curative treatments. The rapid weight regain and metabol…
The development of these incretin-based medications marks a paradigm shift in obesity treatment, offering pharmacological options with efficacy levels previously only achievable through bariatric surgery. This advance…